EligibleTrials

[18F]PI-2620 Phase 3 Histopathological Study

Recruiting · NCT05641688 · Interventional (participants receive a specific treatment) · Lead sponsor: Lantheus Biosciences Ltd.

View the official record on ClinicalTrials.gov →
Alzheimer's disease

Interventions studied

[18F]PI-2620

What this trial is about

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Who can take part

Age range
50 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

25 locations listed across 10 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.